Adma Biologics is a biotechnology company that specializes in the development and manufacturing of immune globulin therapies and other biologics for patients suffering from immune deficiencies and specific infectious diseases
The company focuses on harnessing human plasma to create products that can improve immune response and provide critical support for individuals with compromised immune systems. Through its innovative research and commitment to quality, Adma aims to deliver safe and effective therapies that enhance patient outcomes and overall health.
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California, January 13-16, 2025. ADMA’s presentation will be on Monday, January 13, 2025, at 10:30 a.m. PT.
LOS ANGELES, CA / ACCESSWIRE / December 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQADMA) for violations of the securities laws.
LOS ANGELES, CA / ACCESSWIRE / December 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQADMA) for violations of the securities laws.
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against ADMA Biologics, Inc. (“ADMA Biologics” or the “Company”) (NASDAQADMA) on behalf of ADMA Biologics stockholders. Our investigation concerns whether ADMA Biologics has violated the federal securities laws and/or engaged in other unlawful business practices.
The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA Biologics” or the “Company”) (NASDAQADMA). The investigation concerns whether ADMA and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA Biologics” or the “Company”) (NASDAQADMA). The investigation concerns whether ADMA and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. (“ADMA Biologics” or “the Company”) (NASDAQADMA) for violations of the securities laws.
